With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...

"There is hope, including advances in early detection and treatment spearheaded by retina specialists that can help people ...

Six/UW/Seattle Children’s Cancer Consortium scientists received new funding from the Breast Cancer Research Foundation to ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

In 2025, children within the TEDDY study will submit their final samples at research clinics in Sweden, Finland, Germany and ...

Topline results were announced from a cardiovascular outcomes study evaluating oral semaglutide in patients with type 2 diabetes.

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...

SAN ANTONIO — Treatment with once-weekly semaglutide 2.4 mg (Wegovy ... in people with overweight/obesity and established cardiovascular disease (CVD). The new findings come from prespecified analyses ...

Doctors are currently using stem cells to treat a variety of medical conditions — and that list could soon become even larger ...

For years, scientists have observed a connection between type 2 diabetes and an increased risk of dementia, particularly ...

Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) are a relatively new group of medications originally developed ...